Pricing Log in Create free account

BioAtla, Inc. (BCAB) vs NeuroSense Therapeutics Ltd. (NRSN)

BioAtla, Inc. and NeuroSense Therapeutics Ltd. are both Biotechnology companies. BioAtla, Inc. and NeuroSense Therapeutics Ltd. are of similar size ($2.9M and $2.6M). NeuroSense Therapeutics Ltd. has the higher net margin (0.00% vs −177.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 10 metrics below, NeuroSense Therapeutics Ltd. leads on 7 and BioAtla, Inc. on 3.

Valuation

Metric BCAB NRSN Biotechnology median
P/E n/m n/m 10.60
P/S 0.19 n/m 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 0.69 n/m 9.02
Earnings yield (1,272.50%) (832.79%) (32.88%)
Free cash flow yield (709.98%) (909.43%) (23.13%)

Profitability

Metric BCAB NRSN Biotechnology median
Gross margin 95.44% — 68.51%
Operating margin (180.99%) 0.00% 0.00%
Net margin (177.21%) 0.00% 0.00%
Free cash flow margin (132.29%) 0.00% 0.00%
Return on equity 118.74% 0.00% (51.96%)
Return on assets (171.72%) 0.00% (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BCAB NRSN Biotechnology median
Revenue growth (TTM) 574.65% — 6.76%
EPS growth (last fiscal year) 29.86% 18.52% 29.88%
Revenue growth, 5-year CAGR (28.40%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCAB NRSN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.20 0.28 4.97
Net debt to EBITDA 0.12 0.01 1.01

Dividend

Metric BCAB NRSN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BCAB NRSN Biotechnology median
Market cap 2.89m 2.64m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack